Clinical trial

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

NCT03822351

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-12-19

PhasePHASE2

Study timeline

Study start (actual)2018-12-19Date precision: day

Registry last updated2024-10-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Stage III Non-small Cell Lung Cancerunresolved

Unresectableunresolved

Interventions

Durvalumab + OleclumabDRUG

DurvalumabDRUG · verified · RxNorm: durvalumab

Durvalumab + MonalizumabDRUG

Sponsors & collaborators

MedImmune LLClead sponsor

Mapped research locations

BarcelonaSpain3 New YorkNew York, United States2 MilanItaly2 LodzPoland2 LisbonPortugal2 PortoPortugal2 PhiladelphiaPennsylvania, United States1 TorontoOntario, Canada1 MadridSpain1 PortlandOregon, United States1 MontrealQuebec, Canada1 Washington D.C.District of Columbia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03822351 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.